DSM-Firmenich posts 6% Q2 sales growth as merger synergies boost performance

Dutch‑Swiss ingredients group DSM‑Firmenich announced second‑quarter results that beat market expectations. Like‑for‑like sales rose 6% and adjusted EBITDA reached €466 million, surpassing Bloomberg and Barclays forecasts. Growth was led by the Taste, Texture & Health division (+6%) and the Perfumery & Beauty business (+7%), while the Health, Nutrition & Care segment posted a steadier 4% increase. Management attributed the strong June trading to easing Middle‑East tensions and heightened demand for dairy, beverage and bakery ingredients, as well as preparations for the 2026 FIFA World Cup in North America. CEO Dimitri de Vreeze said fragrance growth would likely moderate to high‑single‑digit percentages in the coming months. The company reaffirmed its full‑year sales outlook, expecting growth at the upper end of its 2‑4% guidance, and disclosed plans to cut roughly 1,000 positions worldwide as it pursues cost synergies from the DSM‑Firmenich merger.